Biomarkers of diastolic dysfunction and myocardial fibrosis: Application to heart failure with a preserved ejection fraction

Journal of Cardiovascular Translational Research

Volumn 6, Issue 4, 2013, Pages 501-515

  Zile, Michael R ^a,b   Baicu, Catalin F ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Biomarkers; Fibrosis; Heart Failure

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; COLLAGEN; COLLAGEN FIBRIL; GALECTIN 3; MICRORNA; ST2 PROTEIN; UNCLASSIFIED DRUG; VALSARTAN;

ARTICLE; COLLAGEN DEGRADATION; COLLAGEN METABOLISM; COLLAGEN SYNTHESIS; DIASTOLIC DYSFUNCTION; DISEASE COURSE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; EXTRACELLULAR MATRIX; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE OVERLOAD; HUMAN; MANAGED CARE; NEEDS ASSESSMENT; NONHUMAN; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CONTENT; PROTEIN PROCESSING; RISK FACTOR; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ANIMALS; BIOLOGICAL MARKERS; FIBRILLAR COLLAGENS; FIBROSIS; HEART FAILURE; HEMODYNAMICS; HUMANS; MYOCARDIUM; NATRIURETIC PEPTIDES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84880514687     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-013-9472-1     Document Type: Article

References (74)

1. Owan, T.; Hodge, D.; Herges, D.; et al. (2006). Heart failure with preserved ejection fraction: trends in prevalence and outcomes. The New England Journal of Medicine, 355, 308.
2. Steinberg, B. A.; Zhao, X.; Heidenreich, P. A.; et al. (2012). Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation, 126, 65-75.
3. Campbell, R.; Jhund, P. S.; Castagno, D.; Hawkins, N. M.; Petrie, M. C.; & McMurray, J. J. V. (2012). What have we learnt about patients with heart failure and preserved ejection fraction (HF-PEF) from DIG-PEF, CHARM-Preserved and I-Preserve? Journal of the American College of Cardiology, 60, 2349-2356.
4. Farr, M. J.; Lang, C. C.; Lamanca, J. J.; Zile, M. R.; Francis, G.; Tavazzi, L.; et al. (2008). Cardiopulmonary exercise variables in diastolic versus systolic heart failure. The American Journal of Cardiology, 102, 203-206.
5. Rector, T. S.; Carson, P. E.; Anand, I. S.; McMurray, J. J.; Zile, M. R.; McKelvie, R. S.; et al. (2012). Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the Minnesota Living with Heart Failure Questionnaire in the I-PRESERVE Trial. Circulation. Heart Failure, 5, 217-225.
6. Zile, M.R.; Kjellstrom, B.; Bennett, T.; Cho, Y.; Baicu, C.; Aaron, M.; Abraham, W.; Bourge, R.C.; Kueffer, F. (2013). Effects of exercise on left ventricular systolic and diastolic properties in patients with heart failure and a preserved ejection fraction versus heart failure and a reduced ejection fraction. Circulation. Heart Failure. doi: 10.1161/CIRCHEARTFAILURE.112.000216.
7. Little, W. C.; & Zile, M. R. (2012). HFpEF: cardiovascular abnormalities not just co-morbidities. Circulation Heart Fail.; 5, 669-671.
8. Gaasch, W. H.; & Zile, M. R. (2011). Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and relative wall thickness. Journal of the American College of Cardiology, 58, 1733-1740.
9. Zile, M. R.; Gottdiener, J. S.; Hetzel, S. J.; McMurray, J. J.; Komajda, M.; McKelvie, R.; et al. (2011). Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation, 124, 2491-2501.
10. Gaasch, W. H.; Delorey, D. E.; Kueffer, F. J.; & Zile, M. R. (2009). Distribution of left ventricular ejection fraction in patients with ischemic and hypertensive heart disease and chronic heart failure. The American Journal of Cardiology, 104, 1413-1415.
11. Aurigemma, G. P.; Zile, M. R.; & Gaasch, W. H. (2006). Contractile behavior in the left ventricle in diastolic heart failure: with emphasis on regional systolic function. Circulation, 113, 296-304.
12. Baicu, C. F.; Zile, M. R.; Aurigemma, G. P.; & Gaasch, W. H. (2005). Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation, 111, 2306-2312.
13. Zile, M. R.; Baicu, C. F.; & Gaasch, W. H. (2004). Diastolic heart failure - abnormalities in active relaxation and passive stiffness of the left ventricle. The New England Journal of Medicine, 350, 1953-1959.
14. Borbely, A.; van der Velden, J.; Papp, Z.; Bronzwaer, J. G.; Edes, I.; Stienen, G. J.; et al. (2005). Cardiomyocyte stiffness in diastolic heart failure. Circulation, 111, 774-781.
15. van Heerebeek, L.; Hamdani, N.; Handoko, M. L.; Falcao-Pires, I.; Musters, R. J.; Kupreishvili, K.; et al. (2008). Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation, 117, 43-51.
16. Westermann, D.; Kasner, M.; Steendijk, P.; Spillmann, F.; Riad, A.; Weitmann, K.; et al. (2008). Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation, 117, 2051-2060.
17. Ahmed, A.; Rich, M. W.; Fleg, J. L.; Zile, M. R.; Young, J. B.; Kitzman, D. W.; et al. (2006). Effects of digoxin on morbidity and mortality in diastolic heart failure: The Ancillary Digitalis Investigation Group Trial. Circulation, 114, 397-403.
18. Yusuf, S.; Pfeffer, M. A.; Swedberg, K.; Granger, C. B.; Held, P.; McMurray, J. J.; et al. (2003). Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM Preserved Trial. The Lancet, 362, 777-781.
19. Cleland, J. G. F.; Tendera, M.; Adamus, J.; Freemantle, N.; Polonski, L.; & Taylor, J. (2006). The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) Study. European Heart Journal, 27, 2338-2345.
20. Massie, B. M.; Carson, P. E.; McMurray, J. J.; Komajda, M.; McKelvie, R.; Zile, M. R.; et al. (2008). Irbesartan in patients with heart failure and preserved ejection fraction. The New England Journal of Medicine, 359, 2456-2467.
21. van Veldhuisen, D. J.; Cohen-Solal, A.; Böhm, M.; Anker, S. D.; Babalis, D.; Roughton, M.; et al. (2009). Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology, 53, 2150-2158.
22. McMurray, J. J.; Adamopoulos, S.; Anker, S. D.; Auricchio, A.; Bohm, M.; Dickstein, K.; et al. (2012). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 33, 1787-1847.
23. Braunwald, E. (2008). Biomarkers in heart failure. The New England Journal of Medicine, 358, 2148-2159.
24. van Kimmenade, R. R.; & Januzzi, J. L. (2012). Emerging biomarkers in heart failure. Clinical Chemistry, 58, 127-138.
25. Azevedo, C. F.; Nigri, M.; Higuchi, M. L.; Pomerantzeff, P. M.; Spina, G. S.; Sampaio, R. O.; et al. (2010). Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. Journal of the American College of Cardiology, 56, 278-287.
26. Spinale, F. G.; Janicki, J. S.; & Zile, M. R. (2013). Membrane-associated matrix proteolysis and heart failure. Circulation Research, 112, 195-208.
27. Spinale, F.G.; Zile, M.R. (2013) Heart failure progression and recognition - categorical considerations for translation research. Circ Res (in press).
28. Wang, T. J.; Wollert, K. C.; Larson, M. G.; Coglianese, E.; McCabe, E. L.; Cheng, S.; et al. (2012). Prognostic utility of novel biomarkers of cardiovascular stress; The Framingham Heart Study. Circulation, 126, 1596-1604.
29. Wang, Y. C.; Yu, C. C.; Chiu, F. C.; Tsai, C. T.; Lai, L. P.; Hwang, J. J.; et al. (2013). Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. J Cardiol Fail.; 19, 163-168.
30. Bhardwaj, A.; & Januzzai, J. L. (2010). ST2: a novel biomarker for heart failure. Expert Review of Molecular Diagnostics, 10, 459-464.
31. deFilippi, C. R.; & Felker, G. M. (2010). Galectin-3 in heart failure - linking fibrosis, remodeling and progression. Euro Cardiology, 6, 33-36.
32. de Boer, R. A.; Lok, D. J.; Jaarsma, T.; van der Meer, P.; Voors, A. A.; Hillege, H. L.; et al. (2011). Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Annals of Medicine, 43, 60-68.
33. Yu, L.; Ruifrok, W. P.; Meissner, M.; Bos, E. M.; van Goor, H.; Sanjabi, B.; et al. (2013). Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circulation. Heart Failure, 6, 107-117.
34. van der Velde, A. R.; Gullestad, L.; Ueland, T.; Aukrust, P.; Guo, Y.; Adourian, A.; et al. (2013). Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circulation Heart Failure, 6, 219-226.
35. van Veldhuisen, D. J.; Linssen, G. C.; Jaarsma, T.; van Gilst, W. H.; Hoes, A. W.; Tijssen, J. G.; et al. (2013). B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. Journal of the American College of Cardiology, 61, 1498-1506.
36. Januzzi, J. L.; Jr.; Rehman, S. U.; Mohammed, A. A.; Bhardwaj, A.; Barajas, L.; Barajas, J.; et al. (2011). Use of amino-terminal pro-b-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. Journal of the American College of Cardiology, 58, 1881-1889.
37. Maisel, A. (2011). Biomonitoring and biomarker-guided therapy: the next step in heart failure and biomarker research. Journal of the American College of Cardiology, 58, 1890-1892.
38. Van Kimmenade, R. R. J.; & Januzzi, J. L. (2012). Using natriuretic peptides to 'guide' therapy in heart failure. Euro Cardiology.; 8, 36-39.
39. Richards, A. M. (2008). Serial measurements of plasma b-type natriuretic peptides: what do they tell us? Journal of the American College of Cardiology, 52, 1004-1005.
40. Maisel, A.; Barnard, D.; Jaski, B.; Frivold, G.; Marais, J.; Azer, M.; et al. (2013). Primary results of the HABIT (HF Assessment with Bnp In The Home) Trial. Journal of the American College of Cardiology, 61, 1726-1735.
41. Lainchbury, J. G.; Troughton, R. W.; Strangman, K. M.; Frampton, C. M.; Pilbrow, A.; Yandle, T. G.; et al. (2009). N-Terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) Trial. Journal of the American College of Cardiology, 55, 53-60.
42. Weiner, R. B.; Baggish, A. L.; Chen-Tournoux, A.; Marshall, J. E.; Gaggin, H. K.; Bhardwaj, A.; et al. (2013). Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) Study. European Journal of Heart Failure, 15, 342-351.
43. Anand, I. S.; Rector, T. S.; Cleland, J. G.; Kuskowski, M.; McKelvie, R. S.; Persson, H.; et al. (2011). Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE Trial. Circulation. Heart Failure, 4, 569-577.
44. McKelvie, R. S.; Komajda, M.; McMurray, J.; Zile, M. R.; Ptaszynska, A.; Donovan, M.; et al. (2010). Baseline plasma NT-proBNP and clinical characteristics: results from the Irbesartan In Heart Failure With Preserved Ejection Fraction Trial. Journal of Cardiac Failure, 16(2), 128-134.
45. Jhund PS, Anand IS, Komajda M, McKelvie RS, Zile MR, Massie B, Carson PE, McMurray JJV. (2013). Change in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-PRESERVE study. Eur Heart J (in press).
46. Iwanaga, Y.; Nishi, I.; Furuichi, S.; Noguchi, T.; Sase, K.; Kihara, Y.; et al. (2006). B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. Journal of the American College of Cardiology, 47(4), 742-748.
47. Zile, M. R.; Bennett, T. D.; St. John Sutton, M.; Cho, Y. K.; Adamson, P. B.; Aaron, M. F.; et al. (2008). Transition from chronic compensated to acute decompensated heart failure: pathophysiologic insights obtained from continuous monitoring of intracardiac pressures. Circulation, 118(14), 1433-1441.
48. Stevenson, L. W.; Zile, M.; Bennett, T. D.; Kueffer, F. J.; Jessup, M. L.; Adamson, P.; et al. (2010). Chronic ambulatory intracardiac pressures and future heart failure events. Circulation. Heart Failure, 3, 580-587.
49. Abraham, W. T.; Adamson, P. B.; Bourge, R. C.; Aaron, M. F.; Costanzo, M. R.; Stevenson, L. W.; et al. (2011). Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. The Lancet, 377, 658-666.
50. Solomon, S. D.; Zile, M. R.; Pieske, B.; Voors, A.; Shah, A.; Kraigher-Krainer, E.; et al. (2012). The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase II randomized-controlled trial. The Lancet, 380, 1387-1395.
51. Chen, H. H.; Glockner, J. F.; Schirger, J. A.; Cataliotti, A.; Redfield, M. M.; & Jr. Burnett, J. C. (2012). Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. Journal of the American College of Cardiology, 60, 2305-2312.
52. O'Connor, C. M.; Starling, R. C.; Hernandez, A. F.; et al. (2011). Effect of nesiritide in patients with acute decompensated heart failure. The New England Journal of Medicine, 365, 32-43.
53. Baicu, C. F.; Li, J.; Zhang, Y.; Kasiganesan, H.; Cooper, G.; Zile, M. R.; et al. (2012). Time course of right ventricular pressure-overload induced myocardial fibrosis: relationship to changes in fibroblast dependent post-synthetic procollagen processing. American Journal of Physiology-Heart and Circulatory Physiology, 303, H1128-H1134. PMCID: In Progress.
54. Zile, M. R.; Baicu, C. F.; Stroud, R. E.; Van Laer, A.; Arroyo, J.; Mukherjee, R.; et al. (2012). Pressure-overload department membrane-type 1 matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. American Journal of Physiology - Heart and Circulatory Physiology, 302, H1429-H1437.
55. Zile, M. R.; DeSantis, S. M.; Baicu, C. F.; Stroud, R. E.; Thompson, S. B.; McClure, C. D.; et al. (2011). Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circulation. Heart Failure, 4, 246-256.
56. Martos, R.; Baugh, J.; Ledwidge, M.; O'Loughlin, C.; Conlon, C.; Patle, A.; et al. (2007). Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation, 115, 888-895.
57. López, B.; González, A.; & Díez, J. (2010). Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation, 121, 1645-1654.
58. González, A.; López, B.; Querejeta, R.; Zubillaga, E.; Echeverría, T.; & Díez, J. (2010). Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension, 55, 1418-1424.
59. Krum, H.; Elsik, M.; Schneider, H. G.; Ptaszynska, A.; Black, M.; Carson, P.; et al. (2011). Relation of peripheral collagen markers to death and hospitalisation in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen sub-study. Cir Heart Fail, 4, 561-568.
60. Bradshaw, A. D.; Baicu, C. F.; Rentz, T. J.; Van Laer, A. O.; Boggs, J.; Lacy, J. M.; et al. (2009). Pressure-overload induced alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. Circulation, 119, 269-280.
61. Bradshaw, A. D.; Baicu, C. F.; Rentz, T. J.; Van Laer, A. O.; Bonnema, D. D.; & Zile, M. R. (2010). Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. American Journal of Physiology - Heart and Circulatory Physiology, 298, H614-H622.
62. Baicu, C. F.; Zhang, Y.; Van Laer, A. O.; Renaud, L.; Zile, M. R.; & Bradshaw, A. D. (2012). Effects of the absence of procollagen C-endopeptidase enhancer-2 (PCOLCE-2) on myocardial collagen accumulation in chronic pressure-overload. American Journal of Physiology - Heart and Circulatory Physiology, 303, H234-H240.
63. Bartunek, J.; Delrue, L.; Van Durme, F.; Muller, O.; Casselman, F.; De Wiest, B.; et al. (2008). Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. Journal of the American College of Cardiology, 52(25), 2166-2174.
64. Manzano-Fernández, S.; Mueller, T.; Pascual-Figal, D.; Truong, Q. A.; & Januzzi, J. L. (2011). Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. The American Journal of Cardiology, 107(2), 259-267.
65. Rehman, S. U.; Mueller, T.; & Januzzi, J. L.; Jr. (2008). Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. Journal of the American College of Cardiology, 52(18), 1458-1465.
66. Gopal, D. M.; Kommineni, M.; Ayalon, N.; Christian Koelbl, C.; Rivka Ayalon, R.; Andreia Biolo, A.; et al. (2012). Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc.; 1, e000760. doi: 10.1161/JAHA.112.000760.
67. Shah, R. V.; Chen-Tournoux, A. A.; Picard, M. H.; van Kimmenade, R. R.; & Januzzi, J. L. (2010). Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. European Journal of Heart Failure, 12(8), 826-832.
68. van Kimmenade, R. R.; Januzzi, J. L.; Jr.; Ellinor, P. T.; Sharma, U. C.; Bakker, J. A.; Low, A. F.; et al. (2006). Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. Journal of the American College of Cardiology, 48(6), 1217-1224.
69. de Boer RA, Van Veldhuisen DJ, deFilippi C, Muntendam P, Adourian AS, Guo Y, Januzzi JL. (2011). Plasma galectin-3 is associated with near-term rehospitalization in heart failure. Poster Abstract #297, 15th Annual Scientific Meeting of the Heart Failure Society of America, Boston, MA, 18-21 Sept
70. Martos, R.; Baugh, J.; Ledwidge, M.; O'Loughlin, C.; Murphy, N. F.; Conlon, C.; et al. (2009). Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. European Journal of Heart Failure, 11(2), 191-197.
71. Barasch, E.; Gottdiener, J. S.; Aurigemma, G.; Kitzman, D. W.; Han, J.; Kop, W. J.; et al. (2009). Association between elevated fibrosis markers and heart failure in the elderly: the Cardiovascular Health Study. Circulation. Heart Failure, 2(4), 303-310.
72. Kitahara, T.; Takeishi, Y.; Arimoto, T.; Niizeki, T.; Koyama, Y.; Sasaki, T.; et al. (2007). Serum carboxy-terminal telopeptide of type I collagen (ICTP) predicts cardiac events in chronic heart failure patients with preserved left ventricular systolic function. Circulation Journal, 71(6), 929-935.
73. Barasch, E.; Gottdiener, J. S.; Aurigemma, G.; Kitzman, D. W.; Han, J.; Kop, W. J.; et al. (2011). The relationship between serum markers of collagen turnover and cardiovascular outcome in the elderly: the Cardiovascular Health Study. Circulation. Heart Failure, 4(6), 733-739.
74. Ahmed, S. H.; Clark, L. L.; Pennington, W. R.; Webb, C. S.; Bonnema, D. D.; Leonardi, A. H.; et al. (2006). Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation, 113(17), 2089-2096.